公司概述
BIO-key International, Inc. specializes in the development and marketing of fingerprint identification biometric technology and software solutions, alongside enterprise-ready identity access management solutions tailored for commercial, government, and education sectors both domestically and internationally. The company operates within the Industrials sector, specifically within the Security & Protection Services industry, which positions it as a provider of critical infrastructure security solutions rather than a consumer-facing technology giant. As of the latest available data, the company's market capitalization stands at $6.08 million, while its trailing twelve-month revenue is reported at $6.10 million, with an employee count listed as not available in current filings. These valuation and revenue metrics indicate that BIO-key operates on a micro-cap scale, suggesting a niche market presence where the firm relies on specialized government and enterprise contracts rather than broad-based mass market adoption to generate its limited revenue stream.
财务健康
The company reported revenue of $6.10 million over the trailing twelve months, yet this generated a net income of -$4,590,370, revealing a severe cost structure where operating expenses and losses significantly outweighed total sales. This disparity is further highlighted by an EBITDA of -$3,908,300, indicating that even before interest and tax considerations, the core operations are currently generating a cash shortfall. The free cash flow stands at -$2,806,292, which implies a lack of financial flexibility and a heavy reliance on external capital sources or cash reserves to fund ongoing operations and maintain liquidity. Margin analysis shows a gross margin of 77.5%, suggesting high value capture on individual units sold, yet this is contrasted by an operating margin of -132.4% and a profit margin of -75.3%, indicating that administrative and overhead costs are excessively high relative to revenue generation. Regarding balance sheet strength, the company holds $2.69 million in cash against total debt of $703,626, resulting in a debt-to-equity ratio of 9.18, which suggests a highly leveraged position where equity is minimal relative to obligations. Despite the high leverage, the current ratio of 1.49 indicates that the company maintains sufficient short-term assets to cover its short-term liabilities, preventing immediate insolvency despite the negative profitability metrics. Furthermore, the return on equity is -80.2% and the return on assets is -27.3%, metrics that reveal that management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
估值评估
Valuation metrics present a complex picture for BIO-key International, Inc., as the trailing P/E ratio is not available due to negative earnings, while the forward P/E is listed as infinity, implying that the market expects earnings to remain negative or that the current price is detached from any near-term profitability projection. The price-to-book ratio stands at 0.79, indicating that the market is currently pricing the company at a discount to its book value, which often occurs when a firm is distressed or lacks consistent earnings power. Alternative valuation measures such as the price-to-sales ratio of 1.00 and an EV/EBITDA of -1.05 provide additional context, suggesting that investors are valuing the company primarily on its revenue base rather than earnings potential, given the negative EBITDA. In terms of trading range, the stock has a 52-week high of $1.97 and a 52-week low of $0.49, meaning the current price sits somewhere within this volatile range, reflecting the high uncertainty surrounding the firm's future performance. The beta value of 0.50 indicates that the stock's price volatility is significantly lower than the broader market, suggesting that BIO-key International, Inc. moves less drastically than the S&P 500, which may be attributed to its small market cap and limited liquidity rather than fundamental stability.
Growth & Income
The company's revenue growth year-over-year is negative at -15.1%, while earnings growth is not available due to the absence of prior period comparables or continued losses, implying that the business is contracting rather than expanding its top line. Since the company does not pay a dividend, with a dividend yield of not available and a payout ratio of 0.0%, it does not return capital to shareholders via distributions but instead retains any minimal or negative earnings to fund operations. This non-dividend status is consistent with the firm's reinvestment strategy, where all available resources are directed toward maintaining its biometric technology infrastructure and securing government contracts rather than providing income to investors. Overall, the growth and income profile of BIO-key International, Inc. is characterized by a contracting revenue base, a complete lack of dividend income, and a reliance on cash reserves to sustain operations during a period of negative earnings and significant revenue decline.